HR+/HER2− breast cancer, which typically retains Rb function and activates the cyclin D–CDK4/6 pathway via estrogen signaling, has the highest sensitivity to CDK4/6 inhibition55. This evidence concerns the gene CDK4 and breast carcinoma.